EMplify June 2020
Multi-system Inflammatory Syndrome in Children (MIS-C) with COVID-19: An Interview with Dr. Ilene Claudius and Dr. Mohsen Saidinejad.

What is it and when did we discover it as an entity?
Have either of you treated anyone with the disease?
Discussion of different cohorts of patients with MIS-C.
Definition of MIS-C.
Shock: cardiogenic and distributive shock presentations.
Fever, is 4 days required?
Discussion of where in the COVID-19 illness MIS-C occurs.
Is clinical shock a requirement?
Screening criteria (labs) and the Children’s Hospital Of Philadelphia pathway.
What is available as treatment?

A discussion of IVIG
Steroids
Cytokine blockers
Remdesivir


Why IVIG?
Complications of the disease.
Why are there more cases in New York?
How has MIS-C changed your practice of testing children?
Is there utility in testing for COVID-19 infection or antibodies in these cases?

 
Resources:EB Medicine Novel 2019 Coronavirus SARS-CoV-2 (COVID-19): An Updated Overview for Emergency Clinicians
EB Medicine COVID-19: The Impact on Pediatric Emergency Care
Children’s Hospital of Philadelphia Clinical Pathway for MIS-C.
Have questions or comments on the podcast? Leave us a voicemail at 678-336-8466, ext 128 or write us at emplify@ebmedicine.net .